SCHEMBL3673930

SCHEMBL3673930

O=C(O)C(c1ccccc1)=S(=O)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 5/20 0.48
CES2 O00748 4/20 0.48
TSHR P16473 2/20 0.48
ALDH1A1 P00352 2/20 0.48
DAO P14920 1/20 0.48
NAPRT Q6XQN6 1/20 0.48
TDP1 Q9NUW8 5/20 0.44
L3MBTL1 Q9Y468 4/20 0.44
MAPT P10636 3/20 0.44
CA2 P00918 3/20 0.44
CA12 O43570 3/20 0.44
CA1 P00915 3/20 0.44
CA9 Q16790 3/20 0.44
CYP3A4 P08684 2/20 0.44
CA4 P22748 2/20 0.44
HSD17B10 Q99714 2/20 0.44
POLB P06746 1/20 0.44
PARP1 P09874 1/20 0.44
CYP2C19 P33261 1/20 0.44
RECQL P46063 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29362245 0.84 ALDH1A1 (0.44) CES1CES2TSHRALDH1A1TDP1
SCHEMBL8830638 0.83 CES2 (0.59) CES1CES2TSHRALDH1A1DAO
SCHEMBL7730406 0.81 CES2 (0.54) CES1CES2TSHRALDH1A1DAO
SCHEMBL11292484 0.81 CES1 (0.44) CES1CES2TSHRALDH1A1DAO
SCHEMBL3386677 0.81 CPT1B (0.54) CES2ALDH1A1TDP1L3MBTL1MAPT
SCHEMBL9206879 0.81 CES1 (0.44) CES1CES2TSHRALDH1A1DAO
SCHEMBL4735121 0.81 TDP1 (0.52) CES1CES2TSHRALDH1A1DAO
SCHEMBL6119974 0.79 ALDH1A1 (0.54) CES1CES2ALDH1A1TDP1MAPT
SCHEMBL3671533 0.79 ALOX15 (0.54) CES1CES2TSHRALDH1A1L3MBTL1
SCHEMBL10438547 0.76 ALDH1A1 (0.39) CES1CES2TSHRALDH1A1DAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11905361-B2 Base proliferating agent, and base-reactive resin composition containing said base proliferating agent NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2024-02-20 US disclosed
US-20220332886-A1 Base Proliferating Agent, and Base-Reactive Resin Composition Containing Said Base Proliferating Agent NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2022-10-20 US disclosed
US-11401370-B2 Base proliferating agent, and base-reactive resin composition containing said base proliferating agent NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2022-08-02 US disclosed
EP-1223923-B1 UNSATURATED ARYL SULFONES FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS UNIV TEMPLE (US) 2010-03-31 EP disclosed
US-7595347-B2 Method for protecting normal cells from cytotoxicity of chemotherapeutic agents Temple University—Of the Commonwealth System of Higher Education (US) 2009-09-29 US disclosed
EP-1370253-B1 USE OF ALPHA, BETA UNSATURATED ARYL SULFONES FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY UNIV TEMPLE (US) 2008-09-03 EP disclosed
EP-1223923-A4 METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS UNIV TEMPLE (US) 2007-09-05 EP disclosed
EP-1027330-B1 STYRYL SULFONE ANTICANCER AGENTS UNIV TEMPLE (US) 2004-12-08 EP disclosed
US-20040214903-A1 Method for protecting normal cells from cytotoxicity of chemotherapeutic agents COSENZA STEPHEN C (US) 2004-10-28 US disclosed
US-6767926-B1 Method for protecting normal cells from cytotoxicity of chemotherapeutic agents TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2004-07-27 US disclosed
US-20030149109-A1 (E)-4-carboxystyrl-4-chlorobenzyl sulfone and pharmaceutical compositions thereof COSENZA STEPHEN C (US) 2003-08-07 US disclosed
US-20030114538-A1 Styryl sulfone anticancer agents TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2003-06-19 US disclosed
US-6548553-B2 Therapy of proliferative disease other than prostate or breast cancer comprising administering styryl sulfone derivative TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2003-04-15 US disclosed
EP-1223923-A1 METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS Temple University of the Commonwealth System of Higher Education (US) 2002-07-24 EP disclosed
US-6359013-B1 BREAST AND PROSTATE CANCER; AFFECT THE MAPK SIGNAL TRANSDUCTION PATHWAY, THEREBY TUMOR CELL GROWTH; INHIBIT THE GROWTH OF TUMOR CELLS WITHOUT AFFECTING NORMAL CELLS; 4-FLUOROSTYRYL 4-BROMOBENZYL SULFONE TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2002-03-19 US disclosed
US-20020022666-A1 Styryl sulfone anticancer agents TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2002-02-21 US disclosed
WO-2001026645-A1 METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2001-04-19 WO disclosed
WO-2000059494-A1 STYRYL SULFONE ANTICANCER AGENTS TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2000-10-12 WO disclosed
EP-1027330-A1 STYRYL SULFONE ANTICANCER AGENTS Temple University of the Commonwealth System of Higher Education (US) 2000-08-16 EP disclosed
WO-1999018068-A1 STYRYL SULFONE ANTICANCER AGENTS TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 1999-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11905361-B2 Base proliferating agent, and base-reactive resin composition containing said base proliferating agent PCNA, MKI67, POLR1A CES1 4586/4885CES2 4335/4885TSHR 2835/4885
US-20030114538-A1 Styryl sulfone anticancer agents BCL2, MCL1, BCL2A1 CES1 1179/4885CES2 1576/4885TSHR 1376/4885
US-20040214903-A1 Method for protecting normal cells from cytotoxicity of chemotherapeutic agents TOP1, TOP2A, PCNA CES1 105/4885CES2 345/4885TSHR 3782/4885
US-20020022666-A1 Styryl sulfone anticancer agents BCL2, MCL1, BCL2A1 CES1 1179/4885CES2 1576/4885TSHR 1376/4885
US-11401370-B2 Base proliferating agent, and base-reactive resin composition containing said base proliferating agent PCNA, MKI67, POLR1A CES1 4586/4885CES2 4335/4885TSHR 2835/4885
US-20220332886-A1 Base Proliferating Agent, and Base-Reactive Resin Composition Containing Said Base Proliferating Agent PCNA, MKI67, POLR1A CES1 4586/4885CES2 4335/4885TSHR 2835/4885
US-20030149109-A1 (E)-4-carboxystyrl-4-chlorobenzyl sulfone and pharmaceutical compositions thereof CCNE1, CCNE2, TOP2B CES1 95/4885CES2 238/4885TSHR 4416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.